Checklists

Implementation checklists collate the key recommendations from clinical guidance to help you easily apply them to your practice. Items may contain pharmaceutical promotional information.

G4P pharmacist counselling checklist

Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information

PP-XAR-GB-2051  April 2021

GLNs prescribers checklist_DVT and PE

Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for treatment of DVT and  PE, and prevention of recurrent DVT and PE in adults.

PP-XAR-GB-2053  April 2021

GLNs prescribers checklist_SPAF

Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*

Commissioned by Bayer plc

This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

PP-XAR-GB-2052  April 2021